RxDoctor Payments Data

Howard Buchoff, MD

Rheumatology · Altamonte Springs, FLNPI 1558558148

Payments from drug & device makers

$775in general payments, 2019–2025

Across 18 payments — averaging $43.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$160
  • Amgen$141
  • Novartis$125
  • AbbVie$111
  • Sanofi$104
  • Lilly USA, LLC$94
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$74696%
  • Education$294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer5$160
Amgen3$141
Novartis1$125
AbbVie2$111
Sanofi2$104
Lilly USA, LLC2$94
Radius Health, Inc.2$29
UCB, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$775 in reported general payments places this provider in the 15th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$1,340,376
Medicare patients
319
Services billed
250,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept49$493,248
RinvoqUpadacitinib18$201,543
Enbrel SureclickEtanercept23$199,099
Humira(Cf) PenAdalimumab18$188,074
OrenciaAbatacept21$183,325
Xeljanz XrTofacitinib Citrate13$97,422
SimponiGolimumab12$84,925
OtezlaApremilast13$59,808
KevzaraSarilumab14$57,115
MethotrexateMethotrexate Sodium190$6,441
Prednisone248$4,084
Hydroxychloroquine Sulfate67$2,583
Leflunomide28$1,835
Celecoxib32$1,701
Tramadol Hcl136$1,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$141$553,05562 claims
AbbVieRinvoq$111$201,54318 claims
SanofiKevzara$104$57,11514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →